SGT-003 is an experimental gene therapy being tested for Duchenne's muscular dystrophy.[1][2][3] It is hoped to be an improvement on Solid Bioscience's earlier gene therapy SGT-001.[4]
{{cite journal}}
|journal=
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.